Cell therapy pioneer Kevin D’Amour, PhD, joins Stemson as Chief Scientific Officer
February 1, 2023
Stemson Therapeutics announced today that Kevin D’Amour has joined the company as Chief Scientific Officer. Kevin has 20 years of experience in cell therapy development, and spent ten years as Chief Scientific Officer at ViaCyte. While at Viacyte, Kevin took three stem cell-derived cell therapy products into the clinic to treat Type 1 Diabetes.